Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (81-90 of 1,111) with videos related to

Pageof 112
Sort By:
American Heart Journal|October 31, 2006
Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) studyKim Fox, Roberto Ferrari, Michal Tendera, et al.
BMC Medical Research Methodology|April 11, 2009
Quality of reporting internal and external validity data from randomized controlled trials evaluating stents for percutaneous coronary interventionMorgane Ethgen, Lsabelle Boutron, Philippe Gabriel Steg, et al.
Archives of Cardiovascular Diseases|September 17, 2023
Relevance of medical information obtained from ChatGPT: Are large language models friends or foes?Jules Mesnier, Gaspard Suc, Neila Sayah, et al.
Progress in Cardiovascular Diseases|April 11, 2025
Incremental benefits of combined inhibition of SGLT1 and SGLT2 with sotagliflozinRam D Bhatt, Bertram Pitt, Ph Gabriel Steg, et al.
Lancet (London, England)|May 27, 2015
Bivalirudin versus heparin use for patients undergoing PPCIPhilippe Gabriel Steg, Arnoud W van't Hof, Uwe Zeymer, et al.
The American Journal of Medicine|January 21, 2019
Real-Life Benefits of Statins for Cardiovascular Prevention in Elderly Subjects: A Population-Based Cohort StudyJulien Bezin, Nicholas Moore, Yohann Mansiaux, et al.
Circulation|November 16, 2020
Response by Schwartz et al to Letter Regarding Article, "Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial"Gregory G Schwartz, Michael Szarek, Vera A Bittner, et al.
Lancet (London, England)|September 2, 2008
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trialKim Fox, Ian Ford, P Gabriel Steg, et al.
Circulation|March 14, 2012
Letter by Mehran et al regarding article, "Bleeding academic research consortium consensus report: the food and drug administration perspective"Roxana Mehran, Philippe Gabriel Steg, Harvey D White, et al.
Trials|May 6, 2009
Reporting of harm in randomized controlled trials evaluating stents for percutaneous coronary interventionMorgane Ethgen, Isabelle Boutron, Philippe Gabriel Steg, et al.
Pageof 112

Showing results (81-90 of 1,111) with videos related to

Sort By:
Pageof 112
American Heart Journal|October 31, 2006
Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) studyKim Fox, Roberto Ferrari, Michal Tendera, et al.
BMC Medical Research Methodology|April 11, 2009
Quality of reporting internal and external validity data from randomized controlled trials evaluating stents for percutaneous coronary interventionMorgane Ethgen, Lsabelle Boutron, Philippe Gabriel Steg, et al.
Archives of Cardiovascular Diseases|September 17, 2023
Relevance of medical information obtained from ChatGPT: Are large language models friends or foes?Jules Mesnier, Gaspard Suc, Neila Sayah, et al.
Progress in Cardiovascular Diseases|April 11, 2025
Incremental benefits of combined inhibition of SGLT1 and SGLT2 with sotagliflozinRam D Bhatt, Bertram Pitt, Ph Gabriel Steg, et al.
Lancet (London, England)|May 27, 2015
Bivalirudin versus heparin use for patients undergoing PPCIPhilippe Gabriel Steg, Arnoud W van't Hof, Uwe Zeymer, et al.
The American Journal of Medicine|January 21, 2019
Real-Life Benefits of Statins for Cardiovascular Prevention in Elderly Subjects: A Population-Based Cohort StudyJulien Bezin, Nicholas Moore, Yohann Mansiaux, et al.
Circulation|November 16, 2020
Response by Schwartz et al to Letter Regarding Article, "Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial"Gregory G Schwartz, Michael Szarek, Vera A Bittner, et al.
Lancet (London, England)|September 2, 2008
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trialKim Fox, Ian Ford, P Gabriel Steg, et al.
Circulation|March 14, 2012
Letter by Mehran et al regarding article, "Bleeding academic research consortium consensus report: the food and drug administration perspective"Roxana Mehran, Philippe Gabriel Steg, Harvey D White, et al.
Trials|May 6, 2009
Reporting of harm in randomized controlled trials evaluating stents for percutaneous coronary interventionMorgane Ethgen, Isabelle Boutron, Philippe Gabriel Steg, et al.
Pageof 112